Caseware UK (AP4) 2024.0.164 2024.0.164 2025-06-302025-06-30false2024-07-01The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.falseManufacture of other inorganic basic chemicals, Manufacture of other organic basic chemicals, Manufacture of other chemical products not elsewhere classified, Other research and experimental development on natural sciences and engineering1510falsetrue 14154914 2024-07-01 2025-06-30 14154914 2023-07-01 2024-06-30 14154914 2025-06-30 14154914 2024-06-30 14154914 2023-07-01 14154914 2 2024-07-01 2025-06-30 14154914 d:Director3 2024-07-01 2025-06-30 14154914 e:Buildings e:LongLeaseholdAssets 2024-07-01 2025-06-30 14154914 e:Buildings e:LongLeaseholdAssets 2025-06-30 14154914 e:Buildings e:LongLeaseholdAssets 2024-06-30 14154914 e:OfficeEquipment 2024-07-01 2025-06-30 14154914 e:OfficeEquipment 2025-06-30 14154914 e:OfficeEquipment 2024-06-30 14154914 e:OfficeEquipment e:OwnedOrFreeholdAssets 2024-07-01 2025-06-30 14154914 e:ComputerEquipment 2024-07-01 2025-06-30 14154914 e:ComputerEquipment 2025-06-30 14154914 e:ComputerEquipment 2024-06-30 14154914 e:ComputerEquipment e:OwnedOrFreeholdAssets 2024-07-01 2025-06-30 14154914 e:OwnedOrFreeholdAssets 2024-07-01 2025-06-30 14154914 e:CurrentFinancialInstruments 2025-06-30 14154914 e:CurrentFinancialInstruments 2024-06-30 14154914 e:CurrentFinancialInstruments e:WithinOneYear 2025-06-30 14154914 e:CurrentFinancialInstruments e:WithinOneYear 2024-06-30 14154914 e:ShareCapital 2024-07-01 2025-06-30 14154914 e:ShareCapital 2025-06-30 14154914 e:ShareCapital 2024-06-30 14154914 e:ShareCapital 2023-07-01 14154914 e:SharePremium 2024-07-01 2025-06-30 14154914 e:SharePremium 2025-06-30 14154914 e:SharePremium 2 2024-07-01 2025-06-30 14154914 e:SharePremium 2024-06-30 14154914 e:SharePremium 2023-07-01 14154914 e:OtherMiscellaneousReserve 2025-06-30 14154914 e:OtherMiscellaneousReserve 2 2024-07-01 2025-06-30 14154914 e:OtherMiscellaneousReserve 2024-06-30 14154914 e:OtherMiscellaneousReserve 2023-07-01 14154914 e:RetainedEarningsAccumulatedLosses 2024-07-01 2025-06-30 14154914 e:RetainedEarningsAccumulatedLosses 2025-06-30 14154914 e:RetainedEarningsAccumulatedLosses 2 2024-07-01 2025-06-30 14154914 e:RetainedEarningsAccumulatedLosses 2023-07-01 2024-06-30 14154914 e:RetainedEarningsAccumulatedLosses 2024-06-30 14154914 e:RetainedEarningsAccumulatedLosses 2023-07-01 14154914 d:OrdinaryShareClass1 2024-07-01 2025-06-30 14154914 d:OrdinaryShareClass1 2025-06-30 14154914 d:OrdinaryShareClass1 2024-06-30 14154914 d:OrdinaryShareClass2 2024-07-01 2025-06-30 14154914 d:OrdinaryShareClass2 2025-06-30 14154914 d:OrdinaryShareClass2 2024-06-30 14154914 d:OrdinaryShareClass3 2024-07-01 2025-06-30 14154914 d:OrdinaryShareClass3 2025-06-30 14154914 d:FRS102 2024-07-01 2025-06-30 14154914 d:AuditExempt-NoAccountantsReport 2024-07-01 2025-06-30 14154914 d:FullAccounts 2024-07-01 2025-06-30 14154914 d:PrivateLimitedCompanyLtd 2024-07-01 2025-06-30 14154914 e:WithinOneYear 2025-06-30 14154914 e:WithinOneYear 2024-06-30 14154914 e:BetweenOneFiveYears 2025-06-30 14154914 e:BetweenOneFiveYears 2024-06-30 14154914 e:ShareCapital 2 2024-07-01 2025-06-30 14154914 f:PoundSterling 2024-07-01 2025-06-30 iso4217:GBP xbrli:shares xbrli:pure

Registered number: 14154914










FLUOROK LIMITED








UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 30 JUNE 2025

 
FLUOROK LIMITED
REGISTERED NUMBER: 14154914

BALANCE SHEET
AS AT 30 JUNE 2025

2025
2024
Note
£
£

Fixed assets
  

Tangible assets
 4 
1,094,256
591,401

  
1,094,256
591,401

Current assets
  

Debtors: amounts falling due within one year
 5 
796,951
374,290

Cash at bank and in hand
 6 
5,450,354
926,245

  
6,247,305
1,300,535

Current Liabilities
  

Creditors: amounts falling due within one year
 7 
(134,789)
(775,342)

Net current assets
  
 
 
6,112,516
 
 
525,193

Total assets less current liabilities
  
7,206,772
1,116,594

  

Net assets
  
7,206,772
1,116,594


Capital and reserves
  

Called up share capital 
 8 
3
2

Share premium account
  
10,597,628
3,000,000

Share-based payment reserve
  
290,018
-

Profit and loss account
  
(3,680,877)
(1,883,408)

  
7,206,772
1,116,594


Page 1

 
FLUOROK LIMITED
REGISTERED NUMBER: 14154914

BALANCE SHEET (CONTINUED)
AS AT 30 JUNE 2025

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




G Pupo
Director

Date: 6 November 2025

The notes on pages 4 to 10 form part of these financial statements.

Page 2

 
FLUOROK LIMITED
 

STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 30 JUNE 2025


Called up share capital
Share premium account
Share-based payment reserve
Profit and loss account
Total equity

£
£
£
£
£


At 1 July 2023
2
3,000,000
-
(734,562)
2,265,440



Loss for the year
-
-
-
(1,148,846)
(1,148,846)



At 1 July 2024
2
3,000,000
-
(1,883,408)
1,116,594



Loss for the year
-
-
-
(1,797,469)
(1,797,469)

Shares issued during the year
1
7,597,628
-
-
7,597,629

Share-based payment charge
-
-
290,018
-
290,018


At 30 June 2025
3
10,597,628
290,018
(3,680,877)
7,206,772


The notes on pages 4 to 10 form part of these financial statements.

Page 3

 
FLUOROK LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2025

1.


General information

Fluorok Limited is a private company limited by share capital and incorporated in England and Wales.
The registered office is Ground Floor, 7400 The Quorum, Alec Issigonis Way, Oxford, OX4 2JZ.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Going concern

In determining the appropriate basis of presentation of the financial statements, the Directors are required to consider whether the Company can continue in operational existence for a period of not less than twelve months from the date of approval of the financial statements. At the year end the Company had net assets of £6.87M, of which £5.45M was cash on hand. The Company has prepared cashflow forecasts to the end of June 2027 which demonstrate that current cash reserves could extend until October 2026. A further funding round is planned in mid 2026  to ensure that it is completed before cash reserves are exhausted. Existing shareholders have already expressed their commitment to the next funding round.
On this basis, the Directors have a reasonable expectation that the Company will be able to continue trading as a going concern for the foreseeable future, and these financial statements have been prepared on the going concern basis. These financial statements do not contain any adjustments that would result if the Company was unable to continue as a going concern.

 
2.3

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

Page 4

 
FLUOROK LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2025

2.Accounting policies (continued)

 
2.4

Government grants

Grants are accounted under the accruals model as permitted by FRS 102. Grants relating to expenditure on tangible fixed assets are credited to profit or loss at the same rate as the depreciation on the assets to which the grant relates. The deferred element of grants is included in creditors as deferred income.
Grants of a revenue nature are recognised in the Statement of Comprehensive Income in the same period as the related expenditure.

 
2.5

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance Sheet. The assets of the plan are held separately from the Company in independently administered funds.

 
2.6

Share-based payments

Where share options are awarded to employees, the fair value of the options at the date of grant is charged to profit or loss over the vesting period. Non-market vesting conditions are taken into account by adjusting the number of equity instruments expected to vest at each balance sheet date so that, ultimately, the cumulative amount recognised over the vesting period is based on the number of options that eventually vest. Market vesting conditions are factored into the fair value of the options granted. The cumulative expense is not adjusted for failure to achieve a market vesting condition.
The fair value of the award also takes into account non-vesting conditions. These are either factors beyond the control of either party (such as a target based on an index) or factors which are within the control of one or other of the parties (such as the Company keeping the scheme open or the employee maintaining any contributions required by the scheme).
Where the terms and conditions of options are modified before they vest, the increase in the fair value of the options, measured immediately before and after the modification, is also charged to profit or loss over the remaining vesting period.
Where equity instruments are granted to persons other than employees, profit or loss is charged with fair value of goods and services received.

 
2.7

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.


Page 5

 
FLUOROK LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2025

2.Accounting policies (continued)

 
2.8

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Long-term leasehold property
-
5 years
Lab equipment
-
3-7 years
Computer equipment
-
3-4 years

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.9

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.10

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.11

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.


3.


Employees

The average monthly number of employees, including directors, during the year was 15 (2024 - 10).

Page 6

 
FLUOROK LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2025

4.


Tangible fixed assets





Long-term leasehold property
Lab equipment
Computer equipment
Total

£
£
£
£



Cost or valuation


At 1 July 2024
-
699,555
13,177
712,732


Additions
142,962
504,295
8,239
655,496



At 30 June 2025

142,962
1,203,850
21,416
1,368,228



Depreciation


At 1 July 2024
-
118,417
2,914
121,331


Charge for the year on owned assets
7,190
141,603
3,848
152,641



At 30 June 2025

7,190
260,020
6,762
273,972



Net book value



At 30 June 2025
135,772
943,830
14,654
1,094,256



At 30 June 2024
-
581,138
10,263
591,401

Page 7

 
FLUOROK LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2025

5.


Debtors

2025
2024
£
£


Trade debtors
32,008
-

Other debtors
288,570
126,448

Prepayments and accrued income
147,316
101,531

Tax recoverable
329,057
146,311

796,951
374,290



6.


Cash and cash equivalents

2025
2024
£
£

Cash at bank and in hand
5,450,354
926,245

5,450,354
926,245



7.


Creditors: Amounts falling due within one year

2025
2024
£
£

Trade creditors
27,347
146,219

Other taxation and social security
28,147
18,569

Other creditors
29,017
608,135

Accruals and deferred income
50,278
2,419

134,789
775,342


Page 8

 
FLUOROK LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2025

8.


Share capital

2025
2024
£
£
Allotted, called up and fully paid



1,000,000 (2024 - 1,000,000) Ordinary shares of £0.000001 each
1
1
779,221 (2024 - 779,221) Seed shares of £0.000001 each
1
1
1,510,331 Ordinary A shares of £0.000001 each
1
-

3

2


On 7th August 2024 1,510,331 Ordinary A shares of £0.000001 were issued for a total consideration of £7,747,998. Costs of £150,369 directly attributable to the share issue were posted to share premium.


9.


Share-based payments

Weighted average exercise price (pence)
2025
Number
2025
Weighted average exercise price
(pence)
2024
Number
2024

Outstanding at the beginning of the year

0.01

123,452

 
-
 
Granted during the year

0.01

141,000

0.01
 
123,452
 
Outstanding at the end of the year
0.01

264,452

0.01
 
123,452
 

During the period, the Company issued 141,000 new share options. The options outstanding at 30 June 2025 had an exercise price of £0.01 and a remaining contractual life of 8-10 years.



2025
2024
£
£


Equity-settled schemes
290,018
-

290,018
-


10.


Pension commitments

The Company operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the Company  in an independently administered fund. The pension cost charge represents contributions payable by the Company to the fund and amounted to £52,204 (2023: £33,479). Contributions totalling £13,032 (2023: £8,135) were payable to the fund at the balance sheet date and are included in creditors.

Page 9

 
FLUOROK LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2025

11.


Commitments under operating leases

At 30 June 2025 the Company had future minimum lease payments due under non-cancellable operating leases for each of the following periods:

2025
2024
£
£


Not later than 1 year
220,883
40,253

Later than 1 year and not later than 5 years
1,287,865
644,040

1,508,748
684,293


12.


Controlling party

There is no one controlling party.


Page 10